Comparison of <scp>SOX</scp> and <scp>CAPOX</scp> in patients with advanced gastric cancer after laparoscopic <scp>D2</scp> gastrectomy: A randomized controlled trial

Xin Liu, Yongjia Yan, Lu Li, Yang Liu, Jun Ma, Xi Wang, Daohan Wang, Bang Liu, Zhuo Liu, Xueying Zhou, He Cui, Zhicheng Zhao, Chuan Li, Jian Liu, Weidong Li, Qingxing Huang, Qun Zhao, Tong Liu, Weihua FuCancer 2024 · DOI

TL;DR

This randomized controlled trial compared two adjuvant chemotherapy regimens, SOX and CAPOX, for patients with advanced gastric cancer following laparoscopic D2 gastrectomy. The study found that SOX was non-inferior to CAPOX in terms of overall survival (OS) and disease-free survival (DFS), suggesting SOX is a viable alternative. Notably, SOX showed potential for improved outcomes in specific patient subgroups, including males, those over 60, and patients with tumors in the gastric antrum or moderately differentiated tumors.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, particularly in Asian populations. While radical gastrectomy with D2 lymphadenectomy is the standard surgical treatment for resectable GC, a substantial portion of patients experience recurrence. Adjuvant chemotherapy after surgery is crucial to improve survival rates, but the optimal regimen for patients undergoing minimally invasive laparoscopic D2 gastrectomy is not definitively established. Previous studies have explored SOX and CAPOX regimens, but this paper specifically investigates their comparative efficacy in the context of laparoscopic surgery, addressing the need for evidence-based chemotherapy choices in this increasingly common surgical approach.

Methods

This was a prospective, randomized, non-inferiority, multicenter trial conducted in China. Patients with advanced GC who underwent laparoscopic D2 gastrectomy were randomly assigned to receive either the SOX (S-1 plus oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) regimen for eight cycles. The primary endpoint was 3-year overall survival (OS), with 3-year disease-free survival (DFS) and chemotherapy-related adverse events as secondary endpoints. The study followed the CONSORT guidelines for reporting. A modified intent-to-treat (mITT) analysis was performed. Statistical analysis included Kaplan-Meier survival curves, log-rank tests, and univariate Cox regression analysis.

Datasets

The study enrolled 144 patients between May 2018 and June 2019 from three centers in China. Of these, 140 patients (69 in the SOX group and 71 in the CAPOX group) were included in the modified intent-to-treat (mITT) analysis. No new datasets or benchmarks were introduced; the study utilized existing patient data collected during the trial.

Key Insights and Ideas

  • SOX as a Viable Alternative: The study establishes SOX as a non-inferior alternative to CAPOX for adjuvant chemotherapy after laparoscopic D2 gastrectomy, offering clinicians another effective option.
  • Subgroup Benefits of SOX: The most compelling insight is the potential for SOX to offer superior outcomes in specific patient populations. This suggests that personalized treatment strategies, considering patient demographics and tumor characteristics, could be beneficial.
  • Laparoscopic Surgery Context: By focusing on patients who underwent laparoscopic D2 gastrectomy, the study addresses a specific and growing surgical population, bridging a potential gap in evidence for adjuvant chemotherapy in this context.
  • Adverse Event Profile: The study found no significant differences in the overall incidence or severity of adverse events between the SOX and CAPOX groups, suggesting a comparable safety profile.

Key Results

  • Overall Survival (OS): The 3-year OS was not significantly different between the SOX and CAPOX groups (HR = 0.48; 95% CI, 0.22–1.06; p=0.071).
  • Disease-Free Survival (DFS): Similarly, the 3-year DFS did not show a significant difference between the groups (HR = 0.66; 95% CI, 0.35–1.24; p=0.200).
  • Subgroup Analysis for OS:
    • Male patients: SOX showed significantly better OS (HR = 0.395; p=0.045).
  • Age >60 years: SOX showed significantly better OS (HR = 0.219; p=0.016).
  • Tumors in the gastric antrum: SOX showed significantly better OS (HR = 0.273; p=0.047).
  • Moderately differentiated tumors: SOX showed significantly better OS (HR = 0.338; p=0.041).
  • Adverse Events: No significant differences were observed in the incidence or severity of adverse events between the two groups. Neutropenia was the most common Grade 3 or 4 adverse event.
  • Recurrence Patterns: No significant differences were found in the distribution of recurrence sites between the two groups. Anastomosis was the most common site of recurrence.

Limitations and Future Work

The authors acknowledge that the small sample sizes in some subgroups limited the robustness of the subgroup analysis. They suggest that future research should include more samples for multivariable Cox regression analysis to further guide the selection of chemotherapy regimens. The study also highlights the need for further investigation into the influence of tumor position on chemotherapy response. Additionally, while laparoscopic surgery did not appear to significantly alter adverse events, ongoing monitoring and research into the long-term impact of minimally invasive techniques on treatment outcomes are warranted.

Summary updated

Abstract

Adjuvant SOX was non-inferior to CAPOX treatments for patients with GC who underwent curative laparoscopic D2 gastrectomy. For male patients, aged >60 years, tumors in the gastric antrum, and moderately differentiated tumors, adjuvant SOX may achieve an improvement compared with CAPOX.
BibTeX
@inproceedings{liu2024comparison,
  author = {Xin Liu and Yongjia Yan and Lu Li and Yang Liu and Jun Ma and Xi Wang and Daohan Wang and Bang Liu and Zhuo Liu and Xueying Zhou and He Cui and Zhicheng Zhao and Chuan Li and Jian Liu and Weidong Li and Qingxing Huang and Qun Zhao and Tong Liu and Weihua Fu},
  title = {{Comparison of <scp>SOX</scp> and <scp>CAPOX</scp> in patients with advanced gastric cancer after laparoscopic <scp>D2</scp> gastrectomy: A randomized controlled trial}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.7326},
}
Figure